Keytruda pembrolizumab: Phase I/II data

Top-line data from 15 patients with BRAF V600 mutation-positive stage III/IV advanced melanoma in the Phase I portion of the

Read the full 209 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE